SEGLENTIS Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Seglentis patents expire, and when can generic versions of Seglentis launch?
Seglentis is a drug marketed by Kowa Pharms and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and five patent family members in thirty-five countries.
The generic ingredient in SEGLENTIS is celecoxib; tramadol hydrochloride. There are twenty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the celecoxib; tramadol hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Seglentis
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 19, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for SEGLENTIS
| International Patents: | 105 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in SEGLENTIS? | SEGLENTIS excipients list |
| DailyMed Link: | SEGLENTIS at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SEGLENTIS
Generic Entry Date for SEGLENTIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SEGLENTIS
| Drug Class | Nonsteroidal Anti-inflammatory Drug Opioid Agonist |
| Mechanism of Action | Cyclooxygenase Inhibitors Full Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for SEGLENTIS
US Patents and Regulatory Information for SEGLENTIS
SEGLENTIS is protected by seven US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEGLENTIS is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SEGLENTIS
Co-crystals of tramadol and coxibis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
Co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Co-crystals of tramadol and coxibs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting SEGLENTIS
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Kowa Pharms | SEGLENTIS | celecoxib; tramadol hydrochloride | TABLET;ORAL | 213426-001 | Oct 15, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SEGLENTIS
When does loss-of-exclusivity occur for SEGLENTIS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 9008
Estimated Expiration: See Plans and Pricing
Australia
Patent: 09304235
Estimated Expiration: See Plans and Pricing
Patent: 10306168
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 0920358
Estimated Expiration: See Plans and Pricing
Patent: 2012005011
Estimated Expiration: See Plans and Pricing
Canada
Patent: 37754
Estimated Expiration: See Plans and Pricing
Patent: 71665
Estimated Expiration: See Plans and Pricing
China
Patent: 2186465
Estimated Expiration: See Plans and Pricing
Patent: 2573825
Estimated Expiration: See Plans and Pricing
Patent: 4817501
Estimated Expiration: See Plans and Pricing
Patent: 4844513
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 11248
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0130316
Estimated Expiration: See Plans and Pricing
Patent: 0161526
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 13956
Estimated Expiration: See Plans and Pricing
Patent: 18374
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 49238
Estimated Expiration: See Plans and Pricing
Patent: 88169
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 12011734
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 77215
Estimated Expiration: See Plans and Pricing
Patent: 49238
Estimated Expiration: See Plans and Pricing
Patent: 88169
Estimated Expiration: See Plans and Pricing
Patent: 86432
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 73380
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 30976
Estimated Expiration: See Plans and Pricing
India
Patent: 35DEN2012
Estimated Expiration: See Plans and Pricing
Israel
Patent: 1785
Estimated Expiration: See Plans and Pricing
Patent: 8256
Estimated Expiration: See Plans and Pricing
Japan
Patent: 99564
Estimated Expiration: See Plans and Pricing
Patent: 45830
Estimated Expiration: See Plans and Pricing
Patent: 12505847
Estimated Expiration: See Plans and Pricing
Patent: 13507402
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 49238
Estimated Expiration: See Plans and Pricing
Malaysia
Patent: 6285
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 6318
Estimated Expiration: See Plans and Pricing
Patent: 11003612
Estimated Expiration: See Plans and Pricing
Patent: 12003050
Estimated Expiration: See Plans and Pricing
Morocco
Patent: 742
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 1873
Estimated Expiration: See Plans and Pricing
Patent: 8353
Estimated Expiration: See Plans and Pricing
Poland
Patent: 49238
Estimated Expiration: See Plans and Pricing
Patent: 88169
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 49238
Estimated Expiration: See Plans and Pricing
Patent: 88169
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 47830
Estimated Expiration: See Plans and Pricing
Patent: 99717
Estimated Expiration: See Plans and Pricing
Patent: 11119608
Estimated Expiration: See Plans and Pricing
Patent: 12120088
Estimated Expiration: See Plans and Pricing
San Marino
Patent: 01300048
Estimated Expiration: See Plans and Pricing
Patent: 01600439
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 8835
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 49238
Estimated Expiration: See Plans and Pricing
Patent: 88169
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1102762
Estimated Expiration: See Plans and Pricing
Patent: 1201892
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1471585
Estimated Expiration: See Plans and Pricing
Patent: 1679400
Estimated Expiration: See Plans and Pricing
Patent: 110069860
Estimated Expiration: See Plans and Pricing
Patent: 120099212
Estimated Expiration: See Plans and Pricing
Spain
Patent: 02112
Estimated Expiration: See Plans and Pricing
Patent: 03962
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 41630
Estimated Expiration: See Plans and Pricing
Patent: 1116273
Estimated Expiration: See Plans and Pricing
Tunisia
Patent: 12000075
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 9534
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SEGLENTIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 5800016 | See Plans and Pricing | |
| Japan | 2013507402 | See Plans and Pricing | |
| New Zealand | 591873 | CO-CRYSTALS OF TRAMADOL AND NSAIDS | See Plans and Pricing |
| South Korea | 101471585 | See Plans and Pricing | |
| Hungary | E030976 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SEGLENTIS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0731795 | 10075033 | Germany | See Plans and Pricing | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
